Reverse Microemulsion-Based Synthesis of (Bis)phosphonate–Metal Materials with Controllable Physical Properties: An Example Using Zoledronic Acid–Calcium Complexes
Source abstract
Abstract
The development of phosphonate-metal materials is tightly related to the advancement in their synthesis methods. Herein, using zoledronic acid (Zol), a bisphosphonate (bioacitve phosphonate with a "P-C-P" structure), and calcium as model molecules, we applied the reverse microemulsion (RM) method to synthesize a series of Zol-Ca complexes. We comprehensively (i) studied the relationship between RM conditions, including the component ratio of RM, cosurfactants, reaction time, reactant concentration, reaction temperature, and the presence of a phospholipid, 1, 2-dioleoyl-sn-glycero-3-phosphate acid (DOPA), and the physical properties of the complexes synthesized (i.e., shape, size, uniformity, monodispersity, and hydrophilicity/hydrophobicity) and (ii) explored the underlying mechanisms. To evaluate the biomedical application potential of the Zol-Ca complexes synthesized, one type of hydrophobic, DOPA-coated spherical Zol-Ca complexes (denoted as Zol-Ca@DOPA) was formulated into a PEGylated lipid-based nanoparticle formulation (i.e., Zol-Ca@bilipid NPs, ∼24 nm in diameter). In a mouse model with orthotopic mammary tumors, the Zol-Ca@bilipid NPs significantly enhanced the distribution of Zol in tumors, as compared to free Zol. It is expected that the RM-based synthesis of (bis)phosphonate-metal materials with controllable physical properties will help expand their applications.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Bone health and treatments · Dendrimers and Hyperbranched Polymers · Radiopharmaceutical Chemistry and Applications
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
The University of Texas at Austin, College of Pharmacy, Division of Pharmaceutics, Austin, Texas 78712, United States
Funding
U.S. Department of Health and Human Services
References (52)
Show source-provided references
1. Clearfield A. · 201110.1039/9781849733571 ↗
2. 10.1016/0022-1902(78)80520-X10.1016/0022-1902(78)80520-X ↗
3. 10.1021/ja804703w10.1021/ja804703w ↗
4. 10.1021/jp309526k10.1021/jp309526k ↗
5. 10.1126/science.123987210.1126/science.1239872 ↗
6. 10.1039/B813344A10.1039/B813344A ↗
7. 10.1098/rsif.2009.0418.focus10.1098/rsif.2009.0418.focus ↗
8. 10.1016/S1359-0286(02)00151-110.1016/S1359-0286(02)00151-1 ↗
9. 10.1039/b802423p10.1039/b802423p ↗
10. 10.1016/j.micromeso.2003.10.01810.1016/j.micromeso.2003.10.018 ↗
11. 10.1039/b506072a10.1039/b506072a ↗
12. 10.1039/c4qi00011k10.1039/c4qi00011k ↗
13. 10.1002/ejic.20040007110.1002/ejic.200400071 ↗
14. 10.1023/A:100963020440710.1023/A:1009630204407 ↗
15. 10.1021/cm049067210.1021/cm0490672 ↗
16. 10.1038/nmat81710.1038/nmat817 ↗
17. 10.1016/j.arabjc.2010.09.02710.1016/j.arabjc.2010.09.027 ↗
18. 10.1070/RC2011v080n10ABEH00415410.1070/RC2011v080n10ABEH004154 ↗
19. 10.1016/j.biomaterials.2014.09.01710.1016/j.biomaterials.2014.09.017 ↗
20. 10.1038/ncomms518210.1038/ncomms5182 ↗
21. 10.1016/j.biomaterials.2015.12.01810.1016/j.biomaterials.2015.12.018 ↗
22. 10.1002/jor.2012910.1002/jor.20129 ↗
23. 10.1093/jnci/djs26310.1093/jnci/djs263 ↗
24. 10.2174/15680090978976028510.2174/156800909789760285 ↗
25. 10.1677/erc.0.011020710.1677/erc.0.0110207 ↗
26. 10.1200/JCO.2003.04.10510.1200/JCO.2003.04.105 ↗
27. 10.1002/cncr.2030810.1002/cncr.20308 ↗
28. 10.1021/acs.molpharmaceut.5b0098710.1021/acs.molpharmaceut.5b00987 ↗
29. 10.1080/10826076.2011.55570010.1080/10826076.2011.555700 ↗
30. 10.1074/jbc.M109.04267110.1074/jbc.M109.042671 ↗
31. 10.1016/j.jconrel.2011.10.02010.1016/j.jconrel.2011.10.020 ↗
32. 10.1021/la961062z10.1021/la961062z ↗
33. 10.1021/la049137j10.1021/la049137j ↗
34. 10.1016/S0169-409X(00)00103-410.1016/S0169-409X(00)00103-4 ↗
35. 10.1038/sj.bjc.660324010.1038/sj.bjc.6603240 ↗
36. 10.1016/j.nano.2011.03.00410.1016/j.nano.2011.03.004 ↗
37. 10.1016/j.jconrel.2013.02.00310.1016/j.jconrel.2013.02.003 ↗
38. 10.1016/j.ijpharm.2010.10.04610.1016/j.ijpharm.2010.10.046 ↗
39. 10.1016/j.biotechadv.2011.06.01810.1016/j.biotechadv.2011.06.018 ↗
40. 10.1166/jbn.2016.221410.1166/jbn.2016.2214 ↗
41. 10.18632/oncotarget.801210.18632/oncotarget.8012 ↗
42. 10.4161/15384047.2014.95598910.4161/15384047.2014.955989 ↗
43. 10.18632/oncotarget.218210.18632/oncotarget.2182 ↗
44. 10.1038/nnano.2007.7010.1038/nnano.2007.70 ↗
45. 10.1021/nn200365a10.1021/nn200365a ↗
46. 10.1039/c2cs15327k10.1039/c2cs15327k ↗
47. 10.1038/nmat239810.1038/nmat2398 ↗
48. 10.1158/2159-8290.CD-14-062110.1158/2159-8290.CD-14-0621 ↗
49. 10.1002/jbmr.154310.1002/jbmr.1543 ↗
50. 10.1021/acs.bioconjchem.5b0036910.1021/acs.bioconjchem.5b00369 ↗
51. 10.1039/c2nj40482f10.1039/c2nj40482f ↗
52. 10.2147/IJN.S3892810.2147/IJN.S38928 ↗